- •CONTENTS
- •Preface
- •Contributors
- •1 Introduction to Toxicology
- •1.1 Definition and Scope, Relationship to Other Sciences, and History
- •1.1.2 Relationship to Other Sciences
- •1.1.3 A Brief History of Toxicology
- •1.3 Sources of Toxic Compounds
- •1.3.1 Exposure Classes
- •1.3.2 Use Classes
- •1.4 Movement of Toxicants in the Environment
- •Suggested Reading
- •2.1 Introduction
- •2.2 Cell Culture Techniques
- •2.2.1 Suspension Cell Culture
- •2.2.2 Monolayer Cell Culture
- •2.2.3 Indicators of Toxicity in Cultured Cells
- •2.3 Molecular Techniques
- •2.3.1 Molecular Cloning
- •2.3.2 cDNA and Genomic Libraries
- •2.3.3 Northern and Southern Blot Analyses
- •2.3.4 Polymerase Chain Reaction (PCR)
- •2.3.5 Evaluation of Gene Expression, Regulation, and Function
- •2.4 Immunochemical Techniques
- •Suggested Reading
- •3.1 Introduction
- •3.2 General Policies Related to Analytical Laboratories
- •3.2.1 Standard Operating Procedures (SOPs)
- •3.2.2 QA/QC Manuals
- •3.2.3 Procedural Manuals
- •3.2.4 Analytical Methods Files
- •3.2.5 Laboratory Information Management System (LIMS)
- •3.3 Analytical Measurement System
- •3.3.1 Analytical Instrument Calibration
- •3.3.2 Quantitation Approaches and Techniques
- •3.4 Quality Assurance (QA) Procedures
- •3.5 Quality Control (QC) Procedures
- •3.6 Summary
- •Suggested Reading
- •4 Exposure Classes, Toxicants in Air, Water, Soil, Domestic and Occupational Settings
- •4.1 Air Pollutants
- •4.1.1 History
- •4.1.2 Types of Air Pollutants
- •4.1.3 Sources of Air Pollutants
- •4.1.4 Examples of Air Pollutants
- •4.1.5 Environmental Effects
- •4.2 Water and Soil Pollutants
- •4.2.1 Sources of Water and Soil Pollutants
- •4.2.2 Examples of Pollutants
- •4.3 Occupational Toxicants
- •4.3.1 Regulation of Exposure Levels
- •4.3.2 Routes of Exposure
- •4.3.3 Examples of Industrial Toxicants
- •Suggested Reading
- •5 Classes of Toxicants: Use Classes
- •5.1 Introduction
- •5.2 Metals
- •5.2.1 History
- •5.2.2 Common Toxic Mechanisms and Sites of Action
- •5.2.3 Lead
- •5.2.4 Mercury
- •5.2.5 Cadmium
- •5.2.6 Chromium
- •5.2.7 Arsenic
- •5.2.8 Treatment of Metal Poisoning
- •5.3 Agricultural Chemicals (Pesticides)
- •5.3.1 Introduction
- •5.3.3 Organochlorine Insecticides
- •5.3.4 Organophosphorus Insecticides
- •5.3.5 Carbamate Insecticides
- •5.3.6 Botanical Insecticides
- •5.3.7 Pyrethroid Insecticides
- •5.3.8 New Insecticide Classes
- •5.3.9 Herbicides
- •5.3.10 Fungicides
- •5.3.11 Rodenticides
- •5.3.12 Fumigants
- •5.3.13 Conclusions
- •5.4 Food Additives and Contaminants
- •5.5 Toxins
- •5.5.1 History
- •5.5.2 Microbial Toxins
- •5.5.3 Mycotoxins
- •5.5.4 Algal Toxins
- •5.5.5 Plant Toxins
- •5.5.6 Animal Toxins
- •5.6 Solvents
- •5.7 Therapeutic Drugs
- •5.8 Drugs of Abuse
- •5.9 Combustion Products
- •5.10 Cosmetics
- •Suggested Reading
- •6 Absorption and Distribution of Toxicants
- •6.1 Introduction
- •6.2 Cell Membranes
- •6.3 Mechanisms of Transport
- •6.3.1 Passive Diffusion
- •6.4 Physicochemical Properties Relevant to Diffusion
- •6.4.1 Ionization
- •6.5 Routes of Absorption
- •6.5.1 Extent of Absorption
- •6.5.2 Gastrointestinal Absorption
- •6.5.3 Dermal Absorption
- •6.5.4 Respiratory Penetration
- •6.6 Toxicant Distribution
- •6.6.1 Physicochemical Properties and Protein Binding
- •6.7 Toxicokinetics
- •Suggested Reading
- •7 Metabolism of Toxicants
- •7.1 Introduction
- •7.2 Phase I Reactions
- •7.2.4 Nonmicrosomal Oxidations
- •7.2.5 Cooxidation by Cyclooxygenases
- •7.2.6 Reduction Reactions
- •7.2.7 Hydrolysis
- •7.2.8 Epoxide Hydration
- •7.2.9 DDT Dehydrochlorinase
- •7.3 Phase II Reactions
- •7.3.1 Glucuronide Conjugation
- •7.3.2 Glucoside Conjugation
- •7.3.3 Sulfate Conjugation
- •7.3.4 Methyltransferases
- •7.3.7 Acylation
- •7.3.8 Phosphate Conjugation
- •Suggested Reading
- •8 Reactive Metabolites
- •8.1 Introduction
- •8.2 Activation Enzymes
- •8.3 Nature and Stability of Reactive Metabolites
- •8.4 Fate of Reactive Metabolites
- •8.4.1 Binding to Cellular Macromolecules
- •8.4.2 Lipid Peroxidation
- •8.4.3 Trapping and Removal: Role of Glutathione
- •8.5 Factors Affecting Toxicity of Reactive Metabolites
- •8.5.1 Levels of Activating Enzymes
- •8.5.2 Levels of Conjugating Enzymes
- •8.5.3 Levels of Cofactors or Conjugating Chemicals
- •8.6 Examples of Activating Reactions
- •8.6.1 Parathion
- •8.6.2 Vinyl Chloride
- •8.6.3 Methanol
- •8.6.5 Carbon Tetrachloride
- •8.6.8 Acetaminophen
- •8.6.9 Cycasin
- •8.7 Future Developments
- •Suggested Reading
- •9.1 Introduction
- •9.2 Nutritional Effects
- •9.2.1 Protein
- •9.2.2 Carbohydrates
- •9.2.3 Lipids
- •9.2.4 Micronutrients
- •9.2.5 Starvation and Dehydration
- •9.2.6 Nutritional Requirements in Xenobiotic Metabolism
- •9.3 Physiological Effects
- •9.3.1 Development
- •9.3.2 Gender Differences
- •9.3.3 Hormones
- •9.3.4 Pregnancy
- •9.3.5 Disease
- •9.3.6 Diurnal Rhythms
- •9.4 Comparative and Genetic Effects
- •9.4.1 Variations Among Taxonomic Groups
- •9.4.2 Selectivity
- •9.4.3 Genetic Differences
- •9.5 Chemical Effects
- •9.5.1 Inhibition
- •9.5.2 Induction
- •9.5.3 Biphasic Effects: Inhibition and Induction
- •9.6 Environmental Effects
- •9.7 General Summary and Conclusions
- •Suggested Reading
- •10 Elimination of Toxicants
- •10.1 Introduction
- •10.2 Transport
- •10.3 Renal Elimination
- •10.4 Hepatic Elimination
- •10.4.2 Active Transporters of the Bile Canaliculus
- •10.5 Respiratory Elimination
- •10.6 Conclusion
- •Suggested Reading
- •11 Acute Toxicity
- •11.1 Introduction
- •11.2 Acute Exposure and Effect
- •11.3 Dose-response Relationships
- •11.4 Nonconventional Dose-response Relationships
- •11.5 Mechanisms of Acute Toxicity
- •11.5.1 Narcosis
- •11.5.2 Acetylcholinesterase Inhibition
- •11.5.3 Ion Channel Modulators
- •11.5.4 Inhibitors of Cellular Respiration
- •Suggested Reading
- •12 Chemical Carcinogenesis
- •12.1 General Aspects of Cancer
- •12.2 Human Cancer
- •12.2.1 Causes, Incidence, and Mortality Rates of Human Cancer
- •12.2.2 Known Human Carcinogens
- •12.3 Classes of Agents Associated with Carcinogenesis
- •12.3.2 Epigenetic Agents
- •12.4 General Aspects of Chemical Carcinogenesis
- •12.5 Initiation-Promotion Model for Chemical Carcinogenesis
- •12.6 Metabolic Activation of Chemical Carcinogens and DNA Adduct Formation
- •12.7 Oncogenes
- •12.8 Tumor Suppressor Genes
- •12.8.1 Inactivation of Tumor Suppressor Genes
- •12.8.2 p53 Tumor Suppressor Gene
- •12.9 General Aspects of Mutagenicity
- •12.10 Usefulness and Limitations of Mutagenicity Assays for the Identification of Carcinogens
- •Suggested Reading
- •13 Teratogenesis
- •13.1 Introduction
- •13.2 Principles of Teratology
- •13.3 Mammalian Embryology Overview
- •13.4 Critical Periods
- •13.5 Historical Teratogens
- •13.5.1 Thalidomide
- •13.5.2 Accutane (Isotetrinoin)
- •13.5.3 Diethylstilbestrol (DES)
- •13.5.4 Alcohol
- •13.6 Testing Protocols
- •13.6.1 FDA Guidelines for Reproduction Studies for Safety Evaluation of Drugs for Human Use
- •13.6.3 Alternative Test Methods
- •13.7 Conclusions
- •Suggested Reading
- •14 Hepatotoxicity
- •14.1 Introduction
- •14.1.1 Liver Structure
- •14.1.2 Liver Function
- •14.2 Susceptibility of the Liver
- •14.3 Types of Liver Injury
- •14.3.1 Fatty Liver
- •14.3.2 Necrosis
- •14.3.3 Apoptosis
- •14.3.4 Cholestasis
- •14.3.5 Cirrhosis
- •14.3.6 Hepatitis
- •14.3.7 Oxidative Stress
- •14.3.8 Carcinogenesis
- •14.4 Mechanisms of Hepatotoxicity
- •14.5 Examples of Hepatotoxicants
- •14.5.1 Carbon Tetrachloride
- •14.5.2 Ethanol
- •14.5.3 Bromobenzene
- •14.5.4 Acetaminophen
- •14.6 Metabolic Activation of Hepatotoxicants
- •Suggested Reading
- •15 Nephrotoxicity
- •15.1 Introduction
- •15.1.1 Structure of the Renal System
- •15.1.2 Function of the Renal System
- •15.2 Susceptibility of the Renal System
- •15.3 Examples of Nephrotoxicants
- •15.3.1 Metals
- •15.3.2 Aminoglycosides
- •15.3.3 Amphotericin B
- •15.3.4 Chloroform
- •15.3.5 Hexachlorobutadiene
- •Suggested Reading
- •16 Toxicology of the Nervous System
- •16.1 Introduction
- •16.2 The Nervous system
- •16.2.1 The Neuron
- •16.2.2 Neurotransmitters and their Receptors
- •16.2.3 Glial Cells
- •16.3 Toxicant Effects on the Nervous System
- •16.3.1 Structural Effects of Toxicants on Neurons
- •16.3.2 Effects of Toxicants on Other Cells
- •16.4 Neurotoxicity Testing
- •16.4.1 In vivo Tests of Human Exposure
- •16.4.2 In vivo Tests of Animal Exposure
- •16.4.3 In vitro Neurochemical and Histopathological End Points
- •16.5 Summary
- •Suggested Reading
- •17 Endocrine System
- •17.1 Introduction
- •17.2 Endocrine System
- •17.2.1 Nuclear Receptors
- •17.3 Endocrine Disruption
- •17.3.1 Hormone Receptor Agonists
- •17.3.2 Hormone Receptor Antagonists
- •17.3.3 Organizational versus Activational Effects of Endocrine Toxicants
- •17.3.4 Inhibitors of Hormone Synthesis
- •17.3.5 Inducers of Hormone Clearance
- •17.3.6 Hormone Displacement from Binding Proteins
- •17.4 Incidents of Endocrine Toxicity
- •17.4.1 Organizational Toxicity
- •17.4.2 Activational Toxicity
- •17.4.3 Hypothyroidism
- •17.5 Conclusion
- •Suggested Reading
- •18 Respiratory Toxicity
- •18.1 Introduction
- •18.1.1 Anatomy
- •18.1.2 Cell Types
- •18.1.3 Function
- •18.2 Susceptibility of the Respiratory System
- •18.2.1 Nasal
- •18.2.2 Lung
- •18.3 Types of Toxic Response
- •18.3.1 Irritation
- •18.3.2 Cell Necrosis
- •18.3.3 Fibrosis
- •18.3.4 Emphysema
- •18.3.5 Allergic Responses
- •18.3.6 Cancer
- •18.3.7 Mediators of Toxic Responses
- •18.4 Examples of Lung Toxicants Requiring Activation
- •18.4.1 Introduction
- •18.4.2 Monocrotaline
- •18.4.3 Ipomeanol
- •18.4.4 Paraquat
- •18.5 Defense Mechanisms
- •Suggested Reading
- •19 Immunotoxicity
- •19.1 Introduction
- •19.2 The Immune System
- •19.3 Immune Suppression
- •19.4 Classification of Immune-Mediated Injury (Hypersensitivity)
- •19.5 Effects of Chemicals on Allergic Disease
- •19.5.1 Allergic Contact Dermatitis
- •19.5.2 Respiratory Allergens
- •19.5.3 Adjuvants
- •19.6 Emerging Issues: Food Allergies, Autoimmunity, and the Developing Immune System
- •Suggested Reading
- •20 Reproductive System
- •20.1 Introduction
- •20.2 Male Reproductive Physiology
- •20.3 Mechanisms and Targets of Male Reproductive Toxicants
- •20.3.1 General Mechanisms
- •20.3.2 Effects on Germ Cells
- •20.3.3 Effects on Spermatogenesis and Sperm Quality
- •20.3.4 Effects on Sexual Behavior
- •20.3.5 Effects on Endocrine Function
- •20.4 Female Reproductive Physiology
- •20.5 Mechanisms and Targets of Female Reproductive Toxicants
- •20.5.1 Tranquilizers, Narcotics, and Social Drugs
- •20.5.2 Endocrine Disruptors (EDs)
- •20.5.3 Effects on Germ Cells
- •20.5.4 Effects on the Ovaries and Uterus
- •20.5.5 Effects on Sexual Behavior
- •Suggested Reading
- •21 Toxicity Testing
- •21.1 Introduction
- •21.2 Experimental Administration of Toxicants
- •21.2.1 Introduction
- •21.2.2 Routes of Administration
- •21.3 Chemical and Physical Properties
- •21.4 Exposure and Environmental Fate
- •21.5 In vivo Tests
- •21.5.1 Acute and Subchronic Toxicity Tests
- •21.5.2 Chronic Tests
- •21.5.3 Reproductive Toxicity and Teratogenicity
- •21.5.4 Special Tests
- •21.6 In vitro and Other Short-Term Tests
- •21.6.1 Introduction
- •21.6.2 Prokaryote Mutagenicity
- •21.6.3 Eukaryote Mutagenicity
- •21.6.4 DNA Damage and Repair
- •21.6.5 Chromosome Aberrations
- •21.6.6 Mammalian Cell Transformation
- •21.6.7 General Considerations and Testing Sequences
- •21.7 Ecological Effects
- •21.7.1 Laboratory Tests
- •21.7.2 Simulated Field Tests
- •21.7.3 Field Tests
- •21.8 Risk Analysis
- •21.9 The Future of Toxicity Testing
- •Suggested Reading
- •22 Forensic and Clinical Toxicology
- •22.1 Introduction
- •22.2 Foundations of Forensic Toxicology
- •22.3 Courtroom Testimony
- •22.4.1 Documentation Practices
- •22.4.2 Considerations for Forensic Toxicological Analysis
- •22.4.3 Drug Concentrations and Distribution
- •22.5 Laboratory Analyses
- •22.5.1 Colorimetric Screening Tests
- •22.5.2 Thermal Desorption
- •22.5.6 Enzymatic Immunoassay
- •22.6 Analytical Schemes for Toxicant Detection
- •22.7 Clinical Toxicology
- •22.7.1 History Taking
- •22.7.2 Basic Operating Rules in the Treatment of Toxicosis
- •22.7.3 Approaches to Selected Toxicoses
- •Suggested Reading
- •23 Prevention of Toxicity
- •23.1 Introduction
- •23.2 Legislation and Regulation
- •23.2.1 Federal Government
- •23.2.2 State Governments
- •23.2.3 Legislation and Regulation in Other Countries
- •23.3 Prevention in Different Environments
- •23.3.1 Home
- •23.3.2 Workplace
- •23.3.3 Pollution of Air, Water, and Land
- •23.4 Education
- •Suggested Reading
- •24 Human Health Risk Assessment
- •24.1 Introduction
- •24.2 Risk Assessment Methods
- •24.2.2 Exposure Assessment
- •24.2.3 Dose Response and Risk Characterization
- •24.3 Noncancer Risk Assessment
- •24.3.1 Default Uncertainty and Modifying Factors
- •24.3.2 Derivation of Developmental Toxicant RfD
- •24.3.3 Determination of RfD and RfC of Naphthalene with the NOAEL Approach
- •24.3.4 Benchmark Dose Approach
- •24.3.5 Determination of BMD and BMDL for ETU
- •24.3.6 Quantifying Risk for Noncarcinogenic Effects: Hazard Quotient
- •24.3.7 Chemical Mixtures
- •24.4 Cancer Risk Assessment
- •24.5 PBPK Modeling
- •Suggested Reading
- •25 Analytical Methods in Toxicology
- •25.1 Introduction
- •25.2 Chemical and Physical Methods
- •25.2.1 Sampling
- •25.2.2 Experimental Studies
- •25.2.3 Forensic Studies
- •25.2.4 Sample Preparation
- •25.2.6 Spectroscopy
- •25.2.7 Other Analytical Methods
- •Suggested Reading
- •26 Basics of Environmental Toxicology
- •26.1 Introduction
- •26.2 Environmental Persistence
- •26.2.1 Abiotic Degradation
- •26.2.2 Biotic Degradation
- •26.2.3 Nondegradative Elimination Processes
- •26.3 Bioaccumulation
- •26.4 Toxicity
- •26.4.1 Acute Toxicity
- •26.4.2 Mechanisms of Acute Toxicity
- •26.4.3 Chronic Toxicity
- •26.4.5 Abiotic and Biotic Interactions
- •26.5 Conclusion
- •Suggested Reading
- •27.1 Introduction
- •27.2 Sources of Toxicants to the Environment
- •27.3 Transport Processes
- •27.3.1 Advection
- •27.3.2 Diffusion
- •27.4 Equilibrium Partitioning
- •27.5 Transformation Processes
- •27.5.1 Reversible Reactions
- •27.5.2 Irreversible Reactions
- •27.6 Environmental Fate Models
- •Suggested Reading
- •28 Environmental Risk Assessment
- •28.1 Introduction
- •28.2 Formulating the Problem
- •28.2.1 Selecting Assessment End Points
- •28.2.2 Developing Conceptual Models
- •28.2.3 Selecting Measures
- •28.3 Analyzing Exposure and Effects Information
- •28.3.1 Characterizing Exposure
- •28.3.2 Characterizing Ecological Effects
- •28.4 Characterizing Risk
- •28.4.1 Estimating Risk
- •28.4.2 Describing Risk
- •28.5 Managing Risk
- •Suggested Reading
- •29 Future Considerations for Environmental and Human Health
- •29.1 Introduction
- •29.2 Risk Management
- •29.3 Risk Assessment
- •29.4 Hazard and Exposure Assessment
- •29.5 In vivo Toxicity
- •29.6 In vitro Toxicity
- •29.7 Biochemical and Molecular Toxicology
- •29.8 Development of Selective Toxicants
- •Glossary
- •Index
COMPARATIVE AND GENETIC EFFECTS |
181 |
9.4.2Selectivity
Selective toxic agents have been developed to protect crops, animals of economic importance, and humans from the vagaries of pests, parasites, and pathogens. Such selectivity is conferred primarily through distribution and comparative biochemistry.
Selectivity through differences in uptake permits the use of an agent toxic to both target and nontarget cells provided that lethal concentrations accumulate only in target cells, leaving nontarget cells unharmed. An example is the accumulation of tetracycline by bacteria but not by mammalian cells, the result being drastic inhibition of protein synthesis in the bacteria, leading to death.
Certain schistosome worms are parasitic in humans and their selective destruction by antimony is accounted for by the differential sensitivity of phosphofructokinase in the two species, the enzyme from schistosomes being more susceptible to inhibition by antimony than is the mammalian enzyme.
Sometimes both target and nontarget species metabolize a xenobiotic by the same pathways but differences in rate determine selectivity. Malathion, a selective insecticide, is metabolically activated by P450 enzymes to the cholinesterase inhibitor malaoxon. In addition to this activation reaction, several detoxication reactions also occur. Carboxylesterase hydrolyzes malathion to form the monoacid, phosphatases hydrolyze the P–O–C linkages to yield nontoxic products, and glutathione S-alkyl- transferase converts malathion to desmethylmalathion. Although all of these reactions occur in both insects and mammals, activation is rapid in both insects and mammals, whereas hydrolysis to the monoacid is rapid in mammals but slow in insects. As a result malaoxon accumulates in insects but not in mammals, resulting in selective toxicity.
A few examples are also available in which the lack of a specific enzyme in some cells in the human body has enabled the development of a therapeutic agent. For example, guanine deaminase is absent from the cells of certain cancers but is abundant in healthy tissue; as a result 8-azaguanine can be used therapeutically.
Distinct differences in cells with regard to the presence or absence of target structures or metabolic processes also offer opportunities for selectivity. Herbicides such as phenylureas, simazine, and so on, block the Hill reaction in chloroplasts, thereby killing plants without harm to animals. This is not always the case because paraquat, which blocks photosynthetic reactions in plants, is a pulmonary toxicant in mammals, due apparently to analogous free-radical reactions (see Figure 18.4) involving enzymes different from those involved in photosynthesis.
9.4.3Genetic Differences
Just as the xenobiotic-metabolizing ability in different animal species seems to be related to evolutionary development and therefore to different genetic constitution, different strains within a species may differ from one another in their ability to metabolize xenobiotics. One reason for differences among strains is that many genes are polymorphic, or exist in multiple forms. A polymorphism is defined as an inherited monogenetic trait that exists in the population in at least two genotypes (two or more stable alleles) and is stably inherited. They arise as the result of a mutational event, and generally result in an altered gene product. The frequency of genetic polymorphisms is arbitrarily defined as having a population frequency of greater than 1%. Many polymorphisms are somewhat race specific, arising with greater frequency in one race than in another.
182 CHEMICAL AND PHYSIOLOGICAL INFLUENCES ON XENOBIOTIC METABOLISM
Observed differences between strains of rats and mice, as described below, may be the result of gene polymorphisms. In cases involving insecticide selection pressure, resistant populations may arise as a result of direct mutations of insecticide-metabolizing enzymes and/or insecticide target sites that are passed on to succeeding generations.
In vivo Toxicity. The toxicity of organic compounds has been found to vary between different strains of laboratory animals. For example, mouse strain C3H is resistant to histamine, the LD50 being 1523 mg/kg in C3H/Jax mice as compared with 230 in Swiss/ICR mice; that is, the animals of the former strain are 6.6 times less susceptible to the effects of histamine. Striking differences in the toxicity of thiourea, a compound used in the treatment of hyperthyroidism, are seen in different strains of the Norway rat. Harvard rats were 11 times more resistant, and wild Norway rats were 335 times more resistant than were rats of the Hopkins strain.
The development of strains resistant to insecticides is an extremely widespread phenomenon that is known to have occurred in more than 200 species of insects and mites, and resistance of up to several 100-fold has been noted. The different biochemical and genetic factors involved have been studied extensively and well characterized. Relatively few vertebrate species are known to have developed pesticide resistance and the level of resistance in vertebrates is low compared to that often found in insects. Susceptible and resistant strains of pine voles exhibit a 7.4-fold difference in endrin toxicity. Similarly pine mice of a strain resistant to endrin were reported to be 12fold more tolerant than a susceptible strain. Other examples include the occurrence of organochlorine insecticide-resistant and susceptible strains of mosquito fish, and resistance to Belladonna in certain rabbit strains.
Several genetic polymorphisms have been recently described and characterized with respect to CYP enzymes. The first and best known example involves CYP2D6. In the course of a clinical trial for debrisoquine, a potential drug for use in lowering blood pressure, Dr. Robert Smith, one of the investigators who used himself as a volunteer, developed severe orthostatic hypotension with blood pressure dropping to 70/50. The effects of the drug persisted for two days, while in other volunteers no adverse effects were noted. Urine analysis demonstrated that in Dr. Smith, debrisoquine was excreted unchanged, while in the other volunteers the primary metabolite was 4- hydroxy debrisoquine. Subsequent studies demonstrated that CYP2D6 was responsible for the formation of 4-hydroxy debrisoquine and that the polymorphic form of 2D6 is prevalent in Caucasians and African-Americans, in which approximately 7% are poor metabolizers. In Asian populations the frequency of poor metabolizers is only 1%.
Another well-known genetic polymorphism has been described in the metabolism of drugs such as isoniazid. “Slow acetylators” are homozygous for a recessive gene; this is believed to lead to the lack of the hepatic enzyme acetyltransferase, which in normal homozygotes or heterozygotes (rapid acetylators) acetylates isoniazid as a step in the metabolism of this drug. This effect is seen also in humans, the gene for slow acetylation showing marked differences in distribution between different human populations. It is very low in Eskimos and Japanese, with 80% to 90% of these populations being rapid acetylators, whereas 40% to 60% of African and some European populations are rapid acetylators. Rapid acetylators often develop symptoms of hepatotoxicity and polyneuritis at the dosage necessary to maintain therapeutic blood levels of isoniazid.
Many other significant polymorphisms in xenobiotic metabolizing enzymes have been described, including those for several CYP genes, alcohol and aldehyde dehydrogenases, epoxide hydrolase, and paraoxonase. One interesting polymorphism affecting
COMPARATIVE AND GENETIC EFFECTS |
183 |
metabolism of dietary trimethylamines involves FMO3. Individuals with FMO3 polymorphisms have a condition known as fish odor syndrome, or trimethylaminurea. Individuals with this syndrome exhibit an objectionable body odor resembling rotting fish due to their inability to N -oxidize trimethylamines, which are found in many foods including meat, eggs, and soybeans. This syndrome often leads to social isolation, clinical depression, and even suicide. Other toxicological implications of this polymorphism are still not known.
Metabolite Production. Strain variations to hexobarbital are often dependant on its degradation rate. For example, male mice of the AL/N strain are long sleepers, and this trait is correlated with slow inactivation of the drug. The reverse is true in CFW/N mice, which have short sleeping time due to rapid hexobarbital oxidation. This close relationship is further evidenced by the fact that the level of brain hexobarbital at awakening is essentially the same in all stains. Similar strain differences have been reported for zoxazolamine paralysis in mice.
Studies on the induction of arylhydrocarbon hydroxylase by 3-methylcholanthrene have revealed several responsive and nonresponsive mouse strains, and it is now well established that the induction of this enzyme is controlled by a single gene. In the accepted nomenclature, Ahb represents the allele for responsiveness, whereas Ahd denotes the allele for nonresponsiveness.
In rats, both age and gender seem to influence strain variation in xenobiotic metabolism. Male rats exhibit about twofold variation between strains in hexobarbital metabolism, whereas female rats may display up to sixfold variation. In either gender the extent of variations depend on age. The ability to metabolize hexobarbital is related to the metabolism of other substrates and the interstrain differences are maintained.
A well-known interstrain difference in phase II reactions is that of glucuronidation in Gunn rats. This is a mutant strain of Wistar rats that is characterized by a severe, genetically determined defect of bilirubin glucuronidation. Their ability to glucuronidate o-aminophenol, o-aminobenzoic acid, and a number of other substrates is also partially defective. This deficiency does not seem to be related to an inability to form UDPGA but rather to the lack of a specific UDP glucuronosyl-transferase. It has been demonstrated that Gunn rats can conjugate aniline by N -glucuronidation and can form the O-glucuronide of p-nitrophenol.
Rabbit strains may exhibit up to 20-fold variation, particularly in the case of hexobarbital, amphetamine, and aminopyrine metabolism. Relatively smaller differences between strains occur with chlorpromazine metabolism. Wild rabbits and California rabbits display the greatest differences from other rabbit strains in hepatic drug metabolism.
Enzyme Differences. Variation in the nature and amount of constitutively expressed microsomal P450s have not been studied extensively in different strains of the same vertebrate. The only thorough investigations, those of the Ah Locus, which controls aryl hydrocarbon hydroxylase induction, have shown that in addition to quantitative differences in the amount of P450 after induction in different strains of mice, there may also be a qualitative difference in the P450 isozymes induced (see Section 9.5.2).
- #15.08.20134.04 Mб14Hastie T., Tibshirani R., Friedman J. - The Elements of Statistical Learning Data Mining, Inference and Prediction (2002)(en).djvu
- #
- #
- #
- #
- #
- #
- #
- #15.08.201315.44 Mб23Hudlicky M, Pavlath A.E. (eds.) - Chemistry of Organic Fluorine Compounds 2[c] A critical Review (1995)(en).djvu
- #
- #